Repurposing Promising Cancer Drugs May Lead to a New Approach to Treating TB

Newswise — Promising experimental cancer chemotherapy drugs may help knock out another life-threatening disease: tuberculosis (TB). A new study published by scientists at Texas Biomedical Research Institute in San Antonio pinpoints a mechanism in regulating cell death called apoptosis that is a potential new target for helping to control the bacterial infection (Mycobacterium tuberculosis or M.tb) that causes the lung disease TB. 

Lead author of the newly-published study, Eusondia Arnett, Ph.D., a Staff Scientist at Texas Biomed, and her colleagues have been testing this theory for about two years. Using human immune cells called macrophages and infecting them with M.tb in the lab, scientists were able to test their theory that pathways regulated by a master regulator of gene expression – a host protein called PPARᵧ -- are a good target for intervention to halt the progression of the disease.

When Dr. Arnett’s team treated M.tb-infected macrophages with Mcl-1 inhibitors that target this important apoptotic pathway, they found a reduction of M.tb growth by 80%. 

Almost 20 people develop TB and four people die from the disease every minute, somewhere in the world. TB is now the world’s deadliest single infectious disease, surpassing AIDS.

“If we can stimulate apoptosis in M.tb-infected cells, then we can reduce M.tb growth, Dr. Arnett explained. “Induction of apoptosis and subsequent reduced M.tb growth should ultimately result in less inflammation and damage to the lungs, and increased control of TB.” 

Tuberculosis infection also creates granulomas in the lungs – dense cellular structures that are the body’s attempt to wall off an infection it is unable to eliminate. However, granulomas also provide a niche for the bacterium to become recalcitrant to antibiotics, Dr. Arnett’s study showed that these experimental cancer drugs also reduced M.tb growth in granulomas using a human granuloma model holding promise for the activity of these drugs in human and animal models. 

Cancer drugs similar to those used in the study are already in Phase II of Food and Drug Administration clinical trials. The next step for testing on the TB front will be to find out the effectiveness of this therapy in a mouse model, and then finally, in a nonhuman primate before moving on to human trials. 

“It’s very exciting that these have already gone through a lot of testing in humans and we can capitalize on that,” Dr. Arnett said, explaining this could speed up the time it takes to get a new treatment to patients with tuberculosis. 

This study is a great example of why basic scientific research is so important,” said senior investigator of the study Dr. Larry Schlesinger, the President & CEO of Texas Biomed. “When we study important host cell pathways for disease, we can find relationships we didn’t even know existed. We can forge new ways to use current knowledge to create novel strategies for host-directed therapy for infection to be used along with antibiotics.” 

The study is published in the June 21, 2018 edition of the Journal PLOS Pathogens. This work was supported in part by a National Institutes of Health T32 Fellowship, “Molecular Mechanisms of Lung Inflammation”, award # T32HL007946 (to EA) and a National Institutes of Health T32 Fellowship, "Interdisciplinary Program in Microbe-Host Biology, award #1-T32-AI-112542 (to EA), and National Institutes of Health grants AI059639 and AI052458 (to LSS).

###

Texas Biomed is one of the world's leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. The Institute is home to the Southwest National Primate Research Center (SNPRC) and provides broad services in primate research. SNPRC contributes to a national network of National Primate Research Centers (NPRCs) with specialized technologies, capabilities and primate resources, many of which are unique to the SNPRC. The Center also serves investigators around the globe with research and technical procedures for collaborative projects. For more information on Texas Biomed, go to www.TxBiomed.org or for more information on SNPRC, visit www.SNPRC.org.